ASKA Pharmaceutical Holdings operates five core business segments—domestic prescription pharmaceuticals, drug discovery, global business, animal health, and testing and around-the-pill services—and is committed to addressing social issues in the healthcare domain.
Through collaboration among these businesses, the Group delivers value across the entire healthcare continuum, from prevention, testing, and diagnosis to treatment and prognosis, while promoting sustainable growth toward the realization of “ASKA VISION 2035.”
The Group’s sources of competitive advantage lie in highly specialized human resources and organizational capabilities, trust from stakeholders, and a strong presence in specialty areas, all of which underpin value creation through its business activities.
Its business model is built upon five key pillars—prescription pharmaceuticals, drug discovery, global business, animal health, and testing and around-the-pill services—which work in an integrated manner to provide comprehensive value across healthcare.
To support this value creation, the Group is addressing six material issues: promotion of a robust business foundation, human capital development, contribution to women’s health and animal health, stable supply of high-quality products and appropriate information provision, respect for human rights, and strengthening of governance.
Through these initiatives, the Group aims to achieve both social and economic value, advance its Mid-Term Management Plan 2028, and enhance corporate value.